Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial. [PDF]
Ruffin AT +26 more
europepmc +1 more source
Determinants of T Cell Exhaustion: How Far Back Can We Go?
Classical versus Emerging models of CD8+ T Cell Exhaustion. Comparison of the classical ‘Endpoint Model’ (Left), where exhaustion is viewed as a terminal state requiring reversal, versus the emerging ‘Trajectory Model’ (Right). Recent studies suggest exhaustion is a continuous developmental path initiated early in infection or tumuorigenesis ...
Testimony Olumade +2 more
wiley +1 more source
Optimising cancer immunotherapy and emerging data supporting de-escalation strategies. [PDF]
Hapuarachi B +4 more
europepmc +1 more source
Five‐year survival impact of adjuvant anti‐PD‐1 therapy in a nationwide cohort of stage III melanoma
This nationwide real‐world cohort study was unable to demonstrate a population‐level survival benefit of adjuvant anti‐PD‐1 in stage III melanoma. Matched analyses suggested higher OS in treated patients. However, limited statistical power and potential residual confounding preclude firm conclusions.
Marie B. Weitemeyer +11 more
wiley +1 more source
Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion
Systematic review of 108 studies with a total of 182 patients with interstitial granulomatous dermatitis (IGD). IGD was frequently associated with systemic conditions or drug exposure. Management includes careful medication review and prompt withdrawal of potential triggers. Corticosteroids (systemic and topical) were commonly effective, while biologic
Francesco Bellinato +4 more
wiley +1 more source
Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study. [PDF]
Ogawa I +17 more
europepmc +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela +6 more
wiley +1 more source
ABSTRACT Background Durvalumab plus tremelimumab (Dur/Tre) has shown promising efficacy in advanced hepatocellular carcinoma (HCC), but predictive biomarkers remain unclear. This study aimed to determine whether early changes in peripheral blood lymphocyte counts during Dur/Tre therapy can predict clinical outcomes.
Yuichi Honma +36 more
wiley +1 more source
Impact of Organ-Specific Severe Immune-Related Adverse Events on Long-Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5-Year Multicenter Multistate Analysis. [PDF]
Tasaki Y +19 more
europepmc +1 more source

